• Novasep, Lysogene Enter Gene Therapy Collaboration contractpharma
    May 28, 2020
    ​Novasep and Lysogene have entered an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1 gangliosidosis, a rare neuronopathic lysosomal storage disorder.
PharmaSources Customer Service